Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.536.

Using Fleximer technology, Mersana Therapeutics has designed an antibody-drug conjugate that specifically recognizes the NaPi2b protein on the surface of cells, explains Bergstrom. In ovarian cancer tumor models, after patients were given either 1 dose or 3 repeated doses of XMT-1536, they showed complete tumor regression.

This agent is expected to be very well tolerated in future clinical trials, says Bergstrom. Initial indications will likely be for patients with more advanced and/or treatment-resistant disease in the metastatic setting, though they also hold promise for earlier forms of therapy and in combination with immune checkpoint agents.

Videos

Donald A. Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses recent data on the new immunoconjugate, XMT-1536.

Donald A. Bergstrom, MD, PhD

Articles

Dr. Bergstrom on XMT-1536 in Ovarian Cancer